Synthesis and Structure Determination of µ-Conotoxin PIIIA Isomers with Different Disulfide Connectivities

Summary

Cysteine-rich peptides fold into distinct three-dimensional structures depending on their disulfide connectivity. Targeted synthesis of individual disulfide isomers is required when buffer oxidation does not lead to the desired disulfide connectivity. The protocol deals with the selective synthesis of 3-disulfide-bonded peptides and their structural analysis using NMR and MS/MS studies.

Abstract

Peptides with a high number of cysteines are usually influenced regarding the three-dimensional structure by their disulfide connectivity. It is thus highly important to avoid undesired disulfide bond formation during peptide synthesis, because it may result in a completely different peptide structure, and consequently altered bioactivity. However, the correct formation of multiple disulfide bonds in a peptide is difficult to obtain by using standard self-folding methods such as conventional buffer oxidation protocols, because several disulfide connectivities can be formed. This protocol represents an advanced strategy required for the targeted synthesis of multiple disulfide-bridged peptides which cannot be synthesized via buffer oxidation in high quality and quantity. The study demonstrates the application of a distinct protecting group strategy for the synthesis of all possible 3-disulfide-bonded peptide isomers of µ-conotoxin PIIIA in a targeted way. The peptides are prepared by Fmoc-based solid phase peptide synthesis using a protecting group strategy for defined disulfide bond formation. The respective pairs of cysteines are protected with trityl (Trt), acetamidomethyl (Acm), and tert-butyl (tBu) protecting groups to make sure that during every oxidation step only the required cysteines are deprotected and linked. In addition to the targeted synthesis, a combination of several analytical methods is used to clarify the correct folding and generation of the desired peptide structures. The comparison of the different 3-disulfide-bonded isomers indicates the importance of accurate determination and knowledge of the disulfide connectivity for the calculation of the three-dimensional structure and for interpretation of the biological activity of the peptide isomers. The analytical characterization includes the exact disulfide bond elucidation via tandem mass spectrometry (MS/MS) analysis which is performed with partially reduced and alkylated derivatives of the intact peptide isomer produced by an adapted protocol. Furthermore, the peptide structures are determined using 2D nuclear magnetic resonance (NMR) experiments and the knowledge obtained from MS/MS analysis.

Introduction

The use of bioactive peptides in pharmaceutical research and development is highly recognized, because they represent potent and highly selective compounds for specific biological targets¹. For their bioactivity, however, the three-dimensional structure is of great importance in order to perform structure-activity relationship studies^2,3,4. Apart from the primary amino acid sequence that influences the overall conformation, disulfide bonds significantly stabilize the structure of cysteine-rich peptides⁵. Multiple disulfide-bridged peptides include conotoxins such as µ-PIIIA from Conus purpurascens which contains six cysteines in its sequence. This high cysteine content theoretically allows the formation of 15 disulfide isomers. The correct disulfide connectivity is very important for the biological activity^6,7. However, the question that arises is whether there is more than one bioactive conformation of naturally occurring peptides and if so, which of those isomers possesses the highest biological activity? In the case of µ-conotoxins, the biological targets are voltage-gated sodium ion channels, and µ-PIIIA in particular is most potent for subtypes Na_V1.2, Na_V1.4 and Na_V1.7³.

The synthesis of disulfide-bridged peptides can be achieved using various methods. The most convenient method for the formation of disulfide bonds within a peptide is the so-called oxidative self-folding approach. Here, the linear precursor of the desired cyclic peptide is synthesized first using solid-phase peptide synthesis, which is after the cleavage from the polymeric support subjected to oxidation in a buffer system. Redox-active agents such as reduced and oxidized glutathione (GSH/GSSG) are often added to promote the formation of the disulfide bonds. The main disadvantage of buffer-supported self-folding is that the disulfide bonds are not formed selectively in a stepwise fashion. Compared to the native peptide, for which often only one specific disulfide isomer is described, it is possible to obtain numerous other isomers with this approach⁸. µ-PIIIA has already been shown to result in at least three differently folded isomers upon self-folding in a previous study³. The separation of such an isomer mixture is rather difficult due to similar retention times if using chromatographic purification methods⁹. The targeted synthesis of a specific isomer is therefore advantageous. To specifically produce an isomer with defined disulfide connectivity, a special strategy is required in which the disulfide bonds are successively closed. Therefore, the linear precursor carrying distinct protecting groups at the individual cysteine pairs is synthesized on the polymer support. After the elimination, the cysteine pairs are individually and successively deprotected and linked in an oxidation reaction to yield the desired disulfide bonds^{10,11,12,13,14,15,16}. After the synthesis and the purification of the reaction product, it is required to confirm the identity and the disulfide connectivity by suitable analytical methods. Numerous analytical methods are available for the elucidation of the primary amino acid sequence, e.g., MS/MS, while the determination of the disulfide connectivity still remains much less investigated. Apart from the complexity of such multiple disulfide-bonded peptides, product-related impurities (e.g., from disulfide scrambling), due to sample preparation and work-up can further complicate analysis. In this paper, we show that the use of a combination of different analytical techniques is necessary to unequivocally clarify the identity of the disulfide bonds in the µ-PIIIA isomers. We have combined chromatographic methods with mass spectrometry and provided the same samples to NMR spectroscopy. In matrix-assisted laser desorption/ionization(MALDI) MS/MS analysis, we identified the disulfide bonds by using partial reduction and iodoacetamide derivatization because top-down analysis is not possible for this peptide. 2D NMR experiments were performed in order to obtain a three-dimensional structure of each isomer. Thus, by combining distinct sophisticated analytical methods, it is possible to elucidate properly the disulfide connectivity and three-dimensional structure of complex multiple disulfide-bonded peptides⁷.

Protocol

Note: All amino acids used herein were in the L-configuration. The abbreviations of amino acids and amino acid derivatives were used according to the recommendations of the Nomenclature Committee of IUB and the IUPAC-IUB Joint Commission on Biochemical Nomenclature.

1. Solid-Phase Peptide Synthesis (SPPS)

NOTE: Carry out the synthesis with a solid-phase peptide synthesizer. Perform the synthesis of the linear peptide precursors of the general sequence ZRLCCGFOKSCRSRQCKOHRCC-NH₂ using a standard protocol for 9-fluorenylmethyloxycarbonyl (Fmoc) chemistry. Apply the following protected amino acids: Pyr(Boc (tert-butyloxycarbonyl)), Arg(Pbf (2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl)), Asn(Trt), Asp(tBu), Hyp(tBu), Lys(Boc), Ser(tBu), Gln(Trt), Glu(tBu), Trp(Boc), Tyr(tBu), Thr(tBu), and His(Trt). Protect the cysteine pairs with Trt-, Acm-, or tBu-groups according to the intended disulfide connectivity.

1. Preparation
   1. Dry the Fmoc Rink-amide resin (loading: 0.28 mmol/g) using a lyophilizer overnight.
   2. Enter the desired peptide sequence (1-letter code) into the program of the synthesizer. The program calculates the required amount for every individual reagent and indicates the solvent quantities.
   3. Weigh the individual reagents (amino acids, HBTU (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate)) according to the protocol and dissolve them in dimethylformamide (DMF) to a final concentration of 0.6 M (amino acids) and 0.6 M (HBTU), respectively.
   4. Transfer the different reagents (amino acids, HBTU, N-methylmorpholine (NMM, 50% in DMF), piperidine (20% in DMF), DMF, dichloromethane (DCM)) to the corresponding vessels and place them in the appropriate rackets of the solid-phase peptide synthesizer.
   5. Add 100 mg of dry resin to the reaction columns and put them in the racket of the synthesizer. Start the solid-phase peptide synthesis.
2. SPPS-Protocol (provided by synthesizer)
   NOTE: The standardized protocol usually applies to 100 mg of resin (loading: 0.53 mmol/g) added to one reaction column for 53 μmol scale leading to the following equivalents: 5 eq. HBTU, 10 eq. NMM, 5 eq. amino acid. In case of PIIIA, however, a loading of 0.28 mmol/g (28 µmol scale) is used, which results in the specified higher equivalents.
   1. Preparation of the resin
      1. Rinse the resin with 2500 µL of DMF, 1400 µL of DCM, and 1400 µL of DMF.
      2. Flush the resin with air until the solvent is removed and rinse the resin with 2500 µL of DMF.
   2. Cleavage of the Fmoc protecting group
      1. Add 20% piperidine in DMF (1000 µL) to the resin and wait for 6 min. Remove the solution from the resin. Repeat Step 1.2.2.1.
      2. Rinse twice with DMF (1^st 4000 µL, 2^nd1400 µL), flush the resin with air until the solvent is removed and rinse twice with 2000 µL of DMF.
   3. Coupling reaction
      1. Mix the following reagents in a separate vial: HBTU (415 µL; 0.6 M in DMF; 249 µmol; 9 eq.), NMM (112 µL; 50% in DMF; 510 µmol; 18 eq.), Fmoc-amino acid (420 µL; 0.6 M in DMF; 252 µmol; 9 eq.). Add the mixture to the resin and wait for 13 min. Remove the solution from the resin. Repeat Step 1.2.3.1.
      2. Wash with 3000 µL of DMF. Wash twice with 1400 µL of DMF. Wash twice with 2000 µL of DMF.
      3. Repeat Steps 1.2.2 and 1.2.3 according to the number of amino acids in the peptide sequence.
   4. Final Fmoc cleavage and resin wash
      1. Add 20% piperidine in DMF (1000 µL) to the resin and wait for 6 min. Remove the solution from the resin. Repeat Step 1.2.4.1.
      2. Rinse twice with DMF (1^st 4000 µL, 2^nd 1400 µL) and flush the resin with air. Rinse twice with 2000 µL of DMF, 4 times with 1400 µL of DCM, and flush twice with air.
3. Work-up
   1. Lyophilize the resin from the reaction columns overnight after the synthesis is complete.

2. Peptide Cleavage from the Resin (Figure 1A)

NOTE: During the cleavage procedure, all amino acid side chains except for Cys(Acm) and Cys(tBu) will be deprotected. The protocol applies to 100 mg of resin.

1. Combine the freeze-dried resin in a 12 ml tube and cool it to 0 °C on ice.
2. Add 150 µL of a scavenger mixture (prepared from 0.75 g phenol, 0.5 mL thioanisole, 0.25 mL ethanedithiol) and 1 mL of trifluoroacetic acid (TFA, 95% in water (H2O)) on ice to the resin. Leave gently shaking for 3 h at room temperature.
3. Filter the mixture through a glass frit and collect the filtrate in tubes individually filled with ice-cold diethyl ether (1 mL of cleavage mixture per 8-10 mL of diethyl ether). The peptide precipitates as a white solid.
4. Rinse the filter cake with additional TFA (95% in H₂O, approx. 1-3 mL).
5. Close the tubes containing the precipitate and centrifuge (3400 x g) the suspensions for 1 min, decant the supernatant and wash the pellets with 8-10 mL of ice-cold diethyl ether. Repeat this step 3 times.
6. Leave the pellets standing without stopper for 5 min to remove remaining traces of diethyl ether. Dissolve the crude product pellets in 1 mL of tert-butanol (80% in H₂O). Freeze-dry the peptides (-80 °C).

3. Purification of the Linear Precursor with Semi-preparative High-performance liquid chromatography (HPLC)

NOTE: Purify the crude peptides by semi-preparative reversed phase (RP) HPLC equipped with a C18 column (5 µm particle size, 100 Å pore size, 250 x 32 mm) and a 3.6 mL injection loop. Use a gradient elution system of 0.1% TFA in H₂O (eluent A) and 0.1% TFA in acetonitrile (MeCN)/H₂O (9:1, eluent B). Detect the peaks at 220 nm.

1. Add approx. 70 mg of the crude peptide to a 15 mL tube and dissolve the solid peptide in the volume of the HPLC sample loop (e.g., 3.6 mL). Use a mixture of 0.1% TFA in MeCN/H₂O (1:1). Vortex until complete dissolution and centrifuge (3400 x g) the solution for 1 min.
2. Draw up the sample (3.6 mL) in a 5 mL syringe and inject the sample without any air bubbles into the injection loop. Inject into the HPLC system. Separate the peptide mixture using a gradient of 0-50% eluent B over 120 min at a flow rate of 10 mL/min.
3. Collect the fractions in individual tubes as they appear. After the run is complete, prepare selected fractions for mass spectrometry (MS) and HPLC analysis (Step 6.1-6.2). Freeze-dry the fractions and store them at -20 °C.
4. After MS and HPLC analysis, combine the pure fractions of linear peptide and prepare the samples for the first oxidation.

4. Selective Formation of the Disulfide Bonds

1. 1 ^st Oxidation (Figure 1B)
   NOTE: During the peptide cleavage from the resin, the Cys(Trt) are deprotected, leading to two unprotected Cys residues which are subsequently subjected to oxidation to form the first disulfide bond. The following protocol applies to 15 mg of linear purified peptide (2864.5 g/mol; 5.2 µmol; 1 eq.).
   1. Dissolve the linear peptide (15 mg) in 105 mL of an isopropanol/H₂O-mixture (1:2; 0.05 mM; pH 8.5 adjusted with sodium hydroxide (NaOH)) and leave gently shaking in air under basic conditions for 12-48 h.
   2. Monitor the oxidation reaction via HPLC and MS. Confirm the formation of the first bridge by iodoacetamide (IAA) derivatization (Step 6).
   3. Freeze-dry the peptide and use it without further purification for the 2^nd oxidation.
2. 2^nd Oxidation (Figure 1C)
   NOTE: During the second oxidation, the deprotection of the Acm-protected cysteines and the formation of the second bridge are catalyzed by iodine. The protocol applies to 15 mg of peptide after the 1^st oxidation (2862.5 g/mol; 5.2 µmol; 1 eq.)
   1. Dissolve the peptide (15 mg; final concentration of 0.05 mM) in 105 mL of an isopropanol/H₂O/1 M hydrochloric acid (HCl) mixture (80:12.5:7.5).
   2. Add 158 µL of a 0.1 M iodine solution in methanol (MeOH) (15.7 µmol; 3 eq.) to the solution. Stir the reaction at room temperature for 3-52 h, i.e., until the oxidation is completed.
   3. Monitor the oxidation reaction via HPLC and MS. Confirm the formation of the second disulfide bond by iodoacetamide (IAA) derivatization (Step 6).
   4. Stop the reaction by adding 79 µL of a 1 M ascorbic acid solution in H₂O (78.8 µmol; 15 eq.). Freeze-dry the reaction mixture and use the powder for the 3^rd oxidation.
3. 3^rd Oxidation (Figure 1D)
   NOTE: The last oxidation leads to the deprotection of the tBu-protected cysteines and to the formation of the third disulfide bridge. The protocol applies to 15 mg of peptide after the 2^nd oxidation (2718.3 g/mol; 5.5 µmol; 1 eq.).
   1. Dissolve the peptide (15 mg, final concentration of 1 mM) in 5.5 mL of TFA. It contains a scavenger mixture consisting of 11.2 mg of diphenylsulfoxide (55 µmol; 10 eq.), 60.2 µL of anisole (0.6 mmol; 100 eq.) and 97.2 µL of trichloromethylsilane (0.8 mmol; 150 eq.). Stir the mixture for 3-5 h at room temperature.
   2. Monitor the oxidation reaction via HPLC and MS. Confirm the formation of the third disulfide bond by iodoacetamide (IAA) derivatization (Step 6).
   3. Precipitate the peptide in the tubes containing cold diethyl ether (0 °C, 1 mL of reaction solution per 8-10 mL of diethyl ether).
   4. Centrifuge the suspensions (3400 x g, 1 min), decant the supernatant, and wash the pellets repeatedly (4 times) with 8-10 mL of cold diethyl ether (0 °C). Let the pellets dry on air (3 min).
   5. Dissolve the pellets in 1 mL of 80% tert-butanol (in H₂O), freeze-dry the peptide and store it at -20 °C.

5. Peptide Purification

NOTE: Purify the oxidized peptides by semi-preparative RP HPLC equipped with a C18 column (10 µm particle size, 300 Å pore size, 250 x 22 mm) and a 3.6 mL injection loop. Use a gradient elution system of 0.1% TFA in H₂O (eluent A) and 0.1% TFA in MeCN/H₂O (9:1, eluent B). Detect the peaks at 220 nm.

1. Add 15 mg of the freeze-dried crude product from Step 4.3.5 to a 15 mL tube. Dissolve the crude product in the volume of the HPLC sample loop (e.g., 3.6 mL). Use a mixture of 0.1% TFA in MeCN/H₂O (1:1). Vortex until complete dissolution and centrifuge (3400 x g) the solution for 1 min.
2. Draw up the 3.6 mL mixture in a 5 mL syringe and inject the sample without any air bubbles into the injection loop. Start the injection into HPLC system. Purify the peptide mixture using a gradient of 0-50% eluent B over 120 min at a flow rate of 10 mL/min.
3. Collect the fractions in individual tubes as they appear. After the run is complete, prepare selected fractions for MS and HPLC analysis (Step 6.1-6.2). Freeze-dry all fractions and store them at -20 °C.
4. After the run is complete, prepare selected fractions for MS and HPLC analysis (Step 6.1-6.2). Freeze-dry all fractions and store them at -20 °C.

6. Peptide Analytics

1. Analytical HPLC
   NOTE: Confirm the purity of a peptide by analytical RP HPLC equipped with a C18 column (5 µm particle size, 300 Å pore size, 250 x 4.6 mm) and a 500 µL injection loop. Use a gradient elution system of 0.1% TFA in H₂O (eluent A) and 0.1% TFA in MeCN (eluent B). Detect the peaks at 220 nm.
   1. Transfer a sample of the peptide fractions or reaction controls into an HPLC vial and dissolve it in a mixture of 0.1% TFA in MeCN/H2O (1:1, 300-500 µL). Place the HPLC vial into the autosampler of the analytical RP HPLC.
   2. Inject 250 µL of each sample. Use a gradient elution system of 0.1% TFA in H₂O (eluent A) and 0.1% TFA in MeCN (eluent B). Purify the peptide using a gradient of 10-40% eluent B over 30 min at a flow rate of 1.0 mL/min.
2. MALDI TOF mass spectrometry
   NOTE: Confirm the identity of a peptide by MALDI TOF (time of flight) mass spectrometry using α-cyano-4-hydroxycinnamic acid as matrix.
   1. Transfer a visible amount of the peptide into a 1.5 mL microcentrifuge tube and dissolve it in 10 µL of a 37 mM α-cyano-4-hydroxycinnamic acid solution in a mixture of 0.1% TFA in H₂O/MeCN (1:1).
   2. Vortex the solution for 10 s, apply 2 µL of the sample to a ground steel target, and air-dry the sample.
   3. Use the reflector mode for the measurements and a peptide calibration standard for molar masses below 6000 g/mol.
3. Iodoacetamide derivatization
   NOTE: As iodoacetamide reacts with thiol groups, iodoacetamide derivatization of the peptides indicates free thiol groups. Hence, the absence of free thiol groups serves as a reaction control via MS during the 1^st oxidation.
   1. Dissolve the peptide in 10 mM phosphate buffer (100 µL; 0.05 mM; pH 7.8) in a 1.5 mL microcentrifuge tube. Add 100 µL of iodoacetamide in 10 mM phosphate buffer (4 mM) to the peptide solution and gently shake the reaction for 2 h at room temperature in the dark. Freeze-dry the reaction mixture and store it at -20 °C.
   2. Use a C18-concentration filter pipette tip and condition the tip with 10 µL of 80% (3 times), 50% (3 times), 30% (3 times) and 0% (3 times) MeCN in H₂O (+ 0.1% TFA).
   3. Dissolve the sample from Step 6.3.1 in 1 µL of 0.1% TFA in H₂O and add the solution to the filter pipette tip. Pipette carefully up and down so that the peptide binds to the bead. Remove the H₂O out of the pipette tip and rinse the filter pipette tip with 10 µL of 0.1% TFA in H₂O.
   4. Add 2 µl of 0.1% TFA in H₂O/MeCN (1:1) with another pipette tip (without filter) on top of the bead which contains the peptide. Apply the filtrate to the ground steel target and air-dry the sample.
   5. Apply 1 µL of a 37 mM α-cyano-4-hydroxycinnamic acid solution in a mixture of 0.1% TFA in H₂O/MeCN (1:1) to the ground steel target with the sample and air-dry the sample.
   6. Use the reflector mode for the measurements and a peptide calibration standard for molar masses below 6000 g/mol.
4. Amino acid analysis
   NOTE: Analyze the exact peptide concentration as well as the amino acid composition of the peptide using an amino acid analyzer.
   1. Transfer 100 µg of the pure peptide (2604 g/mol; 0.04 µmol) to a 1.5 mL microcentrifuge tube and dissolve the powder in 200 µL of 6 M HCl.
   2. Transfer 200 µL of the solution into a glass ampoule and rinse the 1.5 mL microcentrifuge tube twice with 200 µL of 6 M HCl. Transfer the rinsing solution into the glass ampoule as well.
   3. Close the ampoule by heating the neck of the ampoule with a Bunsen burner flame. Put the ampoule into a glass tube. Place it in a heating block for 24 h at 110 °C for hydrolysis.
   4. Open the ampoule and transfer the solution into a 2 mL microcentrifuge tube. Wash the ampoule (3 x 200 µL) and the cap (3 x 100 µL) with double-distilled H₂O and transfer it into the microcentrifuge tube.
   5. Centrifuge the solution for 6 h at 60 °C and 210 x g in a rotational vacuum concentrator. Dissolve the hydrolyzed product in 192 µL of the sample dilution buffer (200 µM) and transfer the solution into a micro-centrifugal filter.
   6. Centrifuge the sample for 1 min at 2300 x g and transfer 100 µL of the filtrate into an amino-acid analysis sample tube. Place the tube into the amino acid analyzer and start the analysis. An amino acid standard is used for calibration.

7. MS/MS Analysis of Disulfide Connectivity

1. Partial reduction and alkylation¹⁷
   1. Dissolve 600 µg of the pure peptide (2604 g/mol; 0.23 µmol) in 1.2 mL of 0.05 M citrate buffer (pH 3.0; 0.14 mM peptide concentration) containing 7.5 mg of tris(2-carboxyethyl)phosphine (TCEP; 0.02 M; 0.03 mmol).
   2. Incubate the mixture at room temperature and take several reaction control samples (100 µL) ranging from 0 min to 30 min.
   3. Mix the samples in a 1.5 mL microcentrifuge tube with 300 µL of alkylation buffer (0.5 M tris-acetate; pH 8.0; 2 mM ethylenediaminetetraacetic acid (EDTA); 1.1 M iodoacetamide) to stop the reaction and perform carbamidomethylation of the free thiol groups.
   4. Stop the reaction after 5 min by adding 100 µL of 10% TFA (in H₂O) and store the samples on dry ice. Prepare HPLC samples as described in Step 6.1.2 and inject 400 µL. (Figure 2A)
   5. Use a gradient elution system of 0.1% TFA in H₂O (eluent A) and 0.1% TFA in MeCN (eluent B). Analyze the peptides using the combination of an isocratic separation (10 % eluent B for 15 min) and then a subsequent gradient of 10-35 % eluent B over 25 min at a flow rate of 10 mL/min. Detect the peaks at 220 nm.
   6. Collect the fractions in 1.5 mL microcentrifuge tubes and freeze-dry the peptides. (Figure 2B)
   7. Transfer a small amount of each fraction to a 1.5 mL microcentrifuge tube for MS/MS analysis of the oxidized forms (continue at Step 7.1.12).
   8. Dissolve the remaining peptide (10-100 µg) in 0.1% TFA in H₂O (10-50 µL) and add an appropriate volume of a 100 mM TCEP solution (in H₂O) to get a final TCEP concentration of 10 mM.
   9. Incubate the reaction for 1 h at 37 °C (Figure 2C). Freeze-dry the reaction mixture and store it at -20 °C.
   10. Prepare MS/MS samples as described in Step 6.3.2-6.3.5.
   11. Perform the MS/MS measurements on a MALDI TOF/TOF mass spectrometer. Use MS/MS LID (laser-induced decay) for fragmentation of the peptide and select the precursor masses of 2- and 4-times carbamidomethylated species. Process and evaluate the MALDI data to confirm the desired disulfide connectivity.

8. NMR Experiments and Structure Analysis

1. Dissolve approx. 0.3-2 mg of the pure peptide product in 500 µL of H₂O/D₂O (90:10) and transfer the mixture into an NMR microtube.
2. Prepare the sample for measurements at an NMR spectrometer
3. Record 2-dimensional [¹H,¹H]-DQF-COSY (double quantum filtered correlation spectroscopy), [¹H,¹H]-TOCSY (total correlated spectroscopy), [¹H,¹H]-NOESY (nuclear Overhauser enhancement spectroscopy), and [¹H,¹³C]-HSQC (heteronuclear single quantum coherence) spectra using water suppression.
4. Assign the proton resonances of the recorded spectra and create the atom assignment from NOESY spectra. Compare the intensities in the NOESY spectra to set the upper-limit distance constraints between different atoms in the peptide. Use the intensity of the germinal protons for peak-intensity calibration.
5. Perform structure calculation and refinement with a computer program for molecular visualizing and use the identified disulfide connectivities of Step 7 as additional restraints (Figure 3).
6. Select the structures with the lowest energies and use it for molecular dynamics (MD) simulations.

Results

15 different disulfide-bridged isomers of the µ-conotoxin PIIIA are synthesized and characterized in detail (Figure 1). Disulfide bonds are identified by partial reduction and subsequent MS/MS analysis (Figure 2). NMR analysis of the different isomers is carried out (Figure 3) to reveal the individual peptide structures. Notably, a combination of RP HPLC, MS/MS fragmentation, and NMR analysis is...

Discussion

The method described herein for the synthesis of cysteine-rich peptides such as µ-PIIIA represents a possibility to selectively produce disulfide-bonded isomers from the same amino acid sequence. Therefore, established methods such as Fmoc-based solid phase peptide synthesis¹⁸ and a defined protecting group strategy for the regioselective formation of disulfide bonds were used¹⁶. The solid-phase peptide synthesis can produce amino acid sequences on a polymer support (r...

Materials

Name	Company	Catalog Number	Comments
Fmoc Rink amide resin	Novabiochem	855001
Pyr(Boc)	Bachem	A-3850
Arg(Pbf)	Iris Biotech	FSC1010
Asn(Trt)	Bachem	B-1785
Asp(tBu)	Iris Biotech	FSP1020
Hyp(tBu)	Iris Biotech	FAA1627
Lys(Boc)	Bachem	B-1080
Ser(tBu)	Iris Biotech	FSC1190
Gln(Trt)	Iris Biotech	FSC1043
Glu(tBu)	Iris Biotech	FSP1045
Trp(Boc)	Iris Biotech	FSC1225
Tyr(tBu)	Sigma Aldrich	47623
Thr(tBu)	Iris Biotech	FSP1210
His(Trt)	Iris Biotech	FDP1200
2-(1H-Benzotriazol-1-yl)-1,1,3,3-tetramethyluroniumhexafluorphosphat	Sigma Aldrich	8510060	Flammable
DMF	Fisher Scientific	D119	Flammable, Toxic
DCM	Fisher Scientific	D37	Carcinogenic
Piperidine	Alfa Aesar	A12442	Flammable, Toxic, Corrosive
N-Methyl-Morpholin	Sigma Aldrich	224286
Cys(Acm)	Iris Biotech	FAA1506
Cys(Trt)	Bachem	E-2495
Cys(tBu)	Bachem	B-1220
trifluoruacetic acid	Sigma Aldrich	74564	Toxic, Corrosive
phenol	Merck	1002060	Toxic
thioanisol	Alfa Aesar	A14846
ethanedithiol	Fluka Analytical	2390
diethyl ether	VWR	100,921	Flammable
tert-butanol	Alfa Aesar	L12338	Flammable
acetonitrile	Fisher Scientific	A998	Flammable
water	Fisher Scientific	W5
isopropanol	VWR	ACRO42383	Flammable
sodium hydroxide	AppliChem	A6579,1000	Corrosive
iodoacetamide	Sigma Aldrich	I6125
iodine	Sigma Aldrich	I0385
Hydrochloric acid	Merck	110165	Corrosive
ascorbic acid	Sigma Aldrich	A4403
diphenylsulfoxide	Sigma Aldrich	P35405
anisol	Sigma Aldrich	96109	Flammable
trichloromethylsilane	Sigma Aldrich	M85301	Flammable
sample dilution buffer	Laborservice Onken
sodium dihydrogen phosphate	Sigma Aldrich	106370
disodium hydrogen phosphate	Sigma Aldrich	795410
(2-carboxyethyl)phosphine hydrochloride	Sigma Aldrich	C4706
citric acid	Sigma Aldrich	251275
sodium citrate dihydrate	Sigma Aldrich	W302600
tris-acetate	Carl Roth,	7125
Ethylenediaminetetraacetic acid	Sigma Aldrich	E26282
peptide calibration standard II	Bruker Daltonics GmbH	8222570
Name of Equipment	Company
solid-phase peptide synthesizer	Intavis Bioanalytical Instruments AG	EPS 221
lyophilizer	Martin Christ GmbH	Alpha 1-2 Ldplus
semipreparative HPLC	Jasco	system PV-987
Eurospher 100 C18 column (RP, 5 µm particle size, 100 Å pore size, 250 x 32 mm)	Knauer	25QE181E2J	purification of the linear peptide
Vydac 218TP1022 column (RP C18, 10 µm particle size, 300 Å pore size, 250 x 22 mm)	Hichrom-VWR	HICH218TP1022	purification of the oxidized peptide
analytical HPLC	Shimadzu	system LC-20AD
Vydac 218TP54 column (C18 RP, 5 µm particle size, 300 Å pore size, 250 x 4.6 mm)	Hichrom-VWR	HICH218TP54	analytical column
ground steel target (MTP 384)	Bruker Daltonics GmbH	NC0910436	MALDI preparation
C18-concentration filter (ZipTip)	Merck KGaA	ZTC18S096	MALDI preparation
MALDI mass spectrometer	Bruker Daltonics GmbH	ultraflex III TOF/TOF
amino acid analyzer	Eppendorf-Biotronik GmbH	LC 3000 system
NMR spectrometer Bruker Avance III	Bruker Daltonics GmbH	Bruker Avance III 600 MHz
computer program for molecular visualising	YASARA Biosciences GmbH	Yasara structures	NMR structure calculation
computer program for MALDI data evaluation	Bruker Daltonics GmbH	flexAnalysis, BioTools	MS/MS fragmentation
analog vortex mixer	VWR	VM 3000
Microcentrifuge	Eppendorf	5410
Centrifuge	Hettich	EBA 20
Rotational vacuum concentrator	Christ	2-18 Cdplus
Analytical Balance	A&D Instruments	GR-202-EC